ImpediMed’s PREVENT Trial Gets An Entry Into Annual Meeting of The American Society Of Breast Surgeons


ImpediMed shares bounced over 28% on the announcement of PREVENT trial being accepted for presentation at the 2019 Annual Meeting of the American Society of Breast Surgeons.

In today’s announcement to ASX, Medical devices manufacturer, ImpediMed Limited (ASX: IPD) stated that the prespecified, detailed interim results of the PREVENT trial will be presented and published during the scientific session of the 2019 Annual Meeting of the American Society of Breast Surgeons (ASBrS). The session will reportedly take place in Dallas, Texas from 30 April to 5 May. 

The company conducted the PREVENT trial for evaluating the impact of BIS on detecting, monitoring and treating cancer-related lymphoedema. Under the trial process, 1,100 breast cancer patients at risk for lymphoedema were randomized for regular monitoring either with BIS or with Tape Measure for up to 3 years post-surgery, told ImpediMed. As of January 2018, the company detected that 109 participants had triggered intervention that includes 68 in the tape measure group and 41 in the BIS group. The patients who met the intervention criteria will reportedly be prescribed compression garments for 28 days.

Richard Carreon, Managing Director, and CEO of ImpediMed said the opportunity to highlight the results of the PREVENT trial at the prestigious ASBrS meeting exemplifies the company’s commitment to improving the quality of care for millions of cancer survivors suffering from lymphoedema worldwide.

ASBrS is a renowned general surgeons’ organization who treat patients with breast disease. The aim of the organization is to introduce continuous advancements in the breast surgery technology. The report said the full PREVENT manuscript has been accepted for publication by the Annals of Surgical Oncology and will be released immediately following the presentation by the PREVENT trial principal investigator.

But the company informed that the results of the PREVENT trial are subject to the embargo policy of the ASBrS 20th Annual Meeting. That means the company could not release the results or any abstract of PREVENT trial before the embargoed time that is slated to 12.30 p.m. Eastern time, 2 May 2019.

Annals of Surgical Oncology is a well-known journal featuring exclusive articles on the latest advancement in the Oncology and Surgery for surgeons from all specialties. The company stated that the full manuscript would provide a detailed analysis of the top-line results previously announced to the market.

Mr. Carreon further said that the company intends to partner with its medical advisors going forward to enhance awareness and improve reimbursement for the detection, monitoring, and treatment of this devastating condition.

The company further informed to hold a discussion in relation to its private payor reimbursement timeline and other information in its upcoming investor conference call on Wednesday, 30 January 2019.

IPD stock has witnessed a negative performance change of 79.46% over the past twelve months including a plunge of 54.76% over past three months.


This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report